Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer
Abstract: Stereotactic body radiotherapy (SBRT) is the precise external delivery of very high-dose radiotherapy to targets in the body, with treatment completed in one to five fractions. SBRT should be an ideal approach for organ-confined prostate cancer because (I) dose escalation should yield impr...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00048/full |
| _version_ | 1811201909441167360 |
|---|---|
| author | Robert eMeier |
| author_facet | Robert eMeier |
| author_sort | Robert eMeier |
| collection | DOAJ |
| description | Abstract: Stereotactic body radiotherapy (SBRT) is the precise external delivery of very high-dose radiotherapy to targets in the body, with treatment completed in one to five fractions. SBRT should be an ideal approach for organ-confined prostate cancer because (I) dose escalation should yield improved rates of cancer control; (II) the unique radiobiology of prostate cancer favors hypofractionation and (III) the conformal nature of SBRT minimizes high-dose radiation delivery to immediately adjacent organs, potentially reducing complications. This approach is also more convenient for patients, and is cheaper than intensity modulated radiotherapy (IMRT). Several external beam platforms are capable of delivering SBRT for early-stage prostate cancer, although most of the mature reported series have employed a robotic non-coplanar platform (i.e., CyberKnife). Several large studies report 5-year biochemical relapse rates which compare favorably to IMRT. Rates of late GU toxicity are similar to those seen with IMRT, and rates of late rectal toxicity may be less than with IMRT and low dose rate (LDR) brachytherapy. Patient-reported quality of life (QOL) outcomes appear similar to IMRT in the urinary domain. Bowel QOL may be less adversely affected by SBRT than with other radiation modalities. After five years of follow-up, SBRT delivered on a robotic platform is yielding outcomes at least as favorable as IMRT, and may be considered appropriate therapy for stage I-II prostate cancer. |
| first_indexed | 2024-04-12T02:29:51Z |
| format | Article |
| id | doaj.art-51594b6f7b6c4b739822c26d7641cba2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T02:29:51Z |
| publishDate | 2015-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-51594b6f7b6c4b739822c26d7641cba22022-12-22T03:51:51ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2015-04-01510.3389/fonc.2015.00048121358Dose-Escalated Robotic SBRT for Stage I-II Prostate CancerRobert eMeier0Swedish Radiosurgery CenterAbstract: Stereotactic body radiotherapy (SBRT) is the precise external delivery of very high-dose radiotherapy to targets in the body, with treatment completed in one to five fractions. SBRT should be an ideal approach for organ-confined prostate cancer because (I) dose escalation should yield improved rates of cancer control; (II) the unique radiobiology of prostate cancer favors hypofractionation and (III) the conformal nature of SBRT minimizes high-dose radiation delivery to immediately adjacent organs, potentially reducing complications. This approach is also more convenient for patients, and is cheaper than intensity modulated radiotherapy (IMRT). Several external beam platforms are capable of delivering SBRT for early-stage prostate cancer, although most of the mature reported series have employed a robotic non-coplanar platform (i.e., CyberKnife). Several large studies report 5-year biochemical relapse rates which compare favorably to IMRT. Rates of late GU toxicity are similar to those seen with IMRT, and rates of late rectal toxicity may be less than with IMRT and low dose rate (LDR) brachytherapy. Patient-reported quality of life (QOL) outcomes appear similar to IMRT in the urinary domain. Bowel QOL may be less adversely affected by SBRT than with other radiation modalities. After five years of follow-up, SBRT delivered on a robotic platform is yielding outcomes at least as favorable as IMRT, and may be considered appropriate therapy for stage I-II prostate cancer.http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00048/fullprostate cancerstereotactic body radiotherapyHypofractionationrobotic radiosurgerystereotactic ablative radiation therapy |
| spellingShingle | Robert eMeier Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer Frontiers in Oncology prostate cancer stereotactic body radiotherapy Hypofractionation robotic radiosurgery stereotactic ablative radiation therapy |
| title | Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer |
| title_full | Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer |
| title_fullStr | Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer |
| title_full_unstemmed | Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer |
| title_short | Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer |
| title_sort | dose escalated robotic sbrt for stage i ii prostate cancer |
| topic | prostate cancer stereotactic body radiotherapy Hypofractionation robotic radiosurgery stereotactic ablative radiation therapy |
| url | http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00048/full |
| work_keys_str_mv | AT robertemeier doseescalatedroboticsbrtforstageiiiprostatecancer |